• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Changes in PT and APTT When Administrating Rivaroxaban, a Direct Inhibitor of Activated Factor X].

作者信息

Nogi Kimiko, Kawasugi Kazuo, Matsuzawa Mayumi, Okufuji Yukiko, Shimadu Chisato, Miyazawa Yukihisa, Furukawa Taiji

出版信息

Rinsho Byori. 2015 Feb;63(2):194-200.

PMID:26529970
Abstract

The effects of oral rivaroxaban (RX), a direct inhibitor of activated factor X (Xa), on prothrombin time (PT) and activated partial thromboplastin time (APTT) were examined. PT and APTT before and after administration of 15 mg RX in 10 healthy subjects were measured by using various reagents. In addition, the blood Xa inhibitor concentration was measured and its correlation with PT and APTT, as measured by each reagent, was examined. Furthermore, the relationship (sensitivity) between the prolongation ratio and FX activity was evaluated. Prolongation of both PT and APTT was observed after RX administration, and maximal prolongation was observed four hours after administration for each reagent. The prolongation ratio was different among the reagents used for examination, and the reagent with the highest sensitivity to FX and factor VII showed the largest prolongation ratio. PT and APTT were positively correlated with RX concentration when measured by any reagent. In this study, neither PT, APTT, nor RX concentration returned to the values measured prior to dosing even at 24 hours after administration of RX. Our results suggest that approximate concentration of remaining RX may be estimated by PT (second) when using a reagent showing a larger prolongation ratio.

摘要

相似文献

1
[Changes in PT and APTT When Administrating Rivaroxaban, a Direct Inhibitor of Activated Factor X].
Rinsho Byori. 2015 Feb;63(2):194-200.
2
Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.每日一次利伐沙班和每日两次阿哌沙班的药代动力学和药效学分离:一项随机交叉研究。
J Thromb Haemost. 2017 Oct;15(10):2017-2028. doi: 10.1111/jth.13801. Epub 2017 Sep 14.
3
Activated Partial Thromboplastin Time or Prothrombin Time Prolongation During Rivaroxaban Administration: Clinical Risk Factors and Outcomes Analysis.利伐沙班治疗期间活化部分凝血活酶时间或凝血酶原时间延长:临床危险因素和结局分析。
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231178546. doi: 10.1177/10760296231178546.
4
Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism.利伐沙班治疗对静脉血栓栓塞症患者ROTEM凝血参数的影响。
Adv Clin Exp Med. 2015 Nov-Dec;24(6):995-1000. doi: 10.17219/acem/42147.
5
Measurement of rivaroxaban concentrations demonstrates lack of clinical utility of a PT, dPT and APTT test in estimating levels.检测利伐沙班的浓度表明,PT、dPT 和 APTT 检测在估计其水平时缺乏临床应用价值。
Int J Lab Hematol. 2018 Aug;40(4):493-499. doi: 10.1111/ijlh.12846. Epub 2018 May 2.
6
Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.接受治疗剂量利伐沙班的患者凝血试验的表现。一项基于血浆峰浓度和谷浓度的横断面药效学研究。
Thromb Haemost. 2014 Jun;111(6):1133-40. doi: 10.1160/TH13-10-0871. Epub 2014 Jan 9.
7
Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.抗Xa因子直接口服抗凝剂阿哌沙班、依度沙班和利伐沙班对凝血检测影响的比较。
Int J Lab Hematol. 2016 Oct;38(5):505-13. doi: 10.1111/ijlh.12528. Epub 2016 Jun 6.
8
Prolongation of prothrombin time in the presence of rivaroxaban: is this the only cause?利伐沙班存在时凝血酶原时间延长:这是唯一原因吗?
Intern Med J. 2017 Feb;47(2):225-227. doi: 10.1111/imj.13343.
9
Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay.口服直接凝血因子Xa抑制剂依度沙班的实验室检测:凝血酶原时间、活化部分凝血活酶时间及凝血酶生成试验的比较
Am J Clin Pathol. 2015 Feb;143(2):241-7. doi: 10.1309/AJCPQ2NJD3PXFTUG.
10
Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.用于评估直接口服抗凝剂药效学抗凝作用的即时检验凝血检测
Ther Drug Monit. 2014 Oct;36(5):624-31. doi: 10.1097/FTD.0000000000000064.